Statera BioPharma (FRA:7CB) Marketable Securities: €0.00 Mil (As of Sep. 2022)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:7CB Statera BioPharma Inc FRA:7CB
20 GF Score
Price €2.61
View Full Analysis

What is Statera BioPharma Marketable Securities?

Statera BioPharma FRA:7CB 20 Marketable Securities is €0.00 Mil as of Sep. 2022. GuruFocus rates FRA:7CB with a GF Score™ of 20/100.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Statera BioPharma's Marketable Securities for the quarter that ended in Sep. 2022 was €0.00 Mil.

Statera BioPharma's annual Marketable Securities stayed the same from Dec. 2019 (€0.00 Mil) to Dec. 2020 (€0.00 Mil) but then increased from Dec. 2020 (€0.00 Mil) to Dec. 2021 (€0.12 Mil).

Statera BioPharma  (FRA:7CB) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

Statera BioPharma Marketable Securities Related Terms

Statera BioPharma Marketable Securities Historical Data

* Premium members only.

The historical data trend for Statera BioPharma's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Statera BioPharma Marketable Securities Chart

Statera BioPharma Annual Data
Trend Dec19 Dec20 Dec21
Marketable Securities
0.00 0.00 0.12

Statera BioPharma Quarterly Data
Dec19 Mar20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 0.20 0.12 0.16 0.15 0.00
FRA:7CB
20GF Score
Statera BioPharma Inc FRA:7CB
Marketable Securities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Statera BioPharma Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Frequently Asked Questions Learn more about Marketable Securities →
What does a Marketable Securities of €0.00 Mil mean?
Statera BioPharma (FRA:7CB) has a Marketable Securities of €0.00 Mil as of Sep. 2022. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Statera BioPharma and its competitors.
Is Statera BioPharma's Marketable Securities too high?
Statera BioPharma's current Marketable Securities is €0.00 Mil. Overall, Statera BioPharma has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Statera BioPharma's Marketable Securities compare to NRBO and PALI?
Statera BioPharma's Marketable Securities of €0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Marketable Securities for a Biotechnology company?
A good Marketable Securities depends on the Biotechnology industry context. However, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Marketable Securities mean?
A high Marketable Securities can signal that a stock is expensive relative to its fundamentals. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Statera BioPharma and its competitors. Statera BioPharma's current Marketable Securities is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Statera BioPharma stock overvalued right now?
Statera BioPharma (FRA:7CB) has a current Marketable Securities of €0.00 Mil. The current Marketable Securities is €0.00 Mil. Statera BioPharma's overall GF Score™ is 20/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Marketable Securities calculated?
Marketable Securities is calculated from a company's financial statements. For Statera BioPharma (FRA:7CB), the current Marketable Securities is €0.00 Mil as of Sep. 2022. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Statera BioPharma Business Description

Address 2580 East Harmony Road, Suite 316, Fort Collins, CO, USA, 80528
Statera BioPharma Inc is a pre-clinical and clinical biopharmaceutical company developing multiple product candidates to address unmet medical needs for use in diseases involving immune system dysfunction. Its proprietary platform of Toll-like receptor drug candidates has applications in mitigation of radiation injury, mitigation of T-cell exhaustion, inflammation, T-cell exhaustion, immune system dysfunction, oncology, infection and neutropenia.
20GF Score

Get the complete analysis for FRA:7CB

Marketable Securities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.61
Price